The stimulant shortage and substitution playbook

What the shortage actually is

The fill failure is not random and it’s not the pharmacist. ADHD stimulants are Schedule II under the Controlled Substances Act, which means the Drug Enforcement Administration (DEA) — not the Food and Drug Administration (FDA), not the manufacturer — sets an annual Aggregate Production Quota (APQ) for each substance, then allocates individual manufacturer quotas inside that ceiling (DEA Federal Register quota notices, 2022–2025²). Manufacturers produce within their allocation; the FDA tracks downstream supply in its Drug Shortages database¹ but does not set production volume.

The FDA formally added immediate-release mixed amphetamine salts (Adderall IR) to the shortage list on October 12, 2022, after Teva reported labour-related production delays. Methylphenidate ER products, lisdexamfetamine after its August 2023 patent expiry, and various other formulations have cycled on and off the list since. As of Q1 2026 multiple amphetamine and methylphenidate products remain listed. Meanwhile US adult stimulant prescriptions grew roughly 58% from 2012 to 2022 — Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR), 2023⁷ — largest growth in adult women 20–39 — against an APQ that has not scaled with that demand. The system is operating as designed under a quota that didn’t move. That framing is what lets you stop interpreting each failed pharmacy call as personal.

What’s actually substitutable

Within-class swaps are dose adjustments; cross-class swaps are clinical events requiring re-titration — and the community charts blur that line. Within-class substitution — Adderall IR to Adderall XR, Adderall to Vyvanse, Ritalin to Concerta — is generally straightforward with dose adjustment and a release-profile match. The drug is the same family; the curve changes. Cross-class substitution — amphetamine to methylphenidate, or stimulant to non-stimulant — is not a swap. Roughly 25–35% of patients respond preferentially to one stimulant class over the other (Hodgkins et al., 2012⁵); switching classes is a clinical event that requires re-titration. The big efficacy citation underneath everything is Cortese et al., 2018, Lancet Psychiatry⁴: in adults, amphetamines show the strongest effect (around 0.79), methylphenidate moderate (~0.49), atomoxetine (~0.45), and modafinil weakest (~0.16).

Working dose-equivalence approximations — not FDA-approved, clinical convention only, always confirm with a prescriber: Adderall IR 10 mg ≈ Adderall XR 10 mg (smoother curve) ≈ Vyvanse 30 mg ≈ Dexedrine 7.5 mg. Methylphenidate IR 10 mg ≈ Concerta 18 mg ≈ Focalin 5 mg. None of these are interchangeable in a strict sense; they are starting points for a conversation, drawn from clinical references like the American Academy of Family Physicians (AAFP) 2020 review on adult ADHD pharmacotherapy¹⁰ and Stahl’s prescriber’s guide. The community-circulated swap charts that look definitive are not.

The playbook

Before you need it. Ask the prescriber to write the script with the earliest legal fill date — usually day 28 of the prior fill at 80% used. Confirm they are set up for EPCS (Electronic Prescribing for Controlled Substances)³; the August 2023 DEA pharmacy-to-pharmacy transfer rule requires it on both ends. Know your exact medication: drug, salt, mg, formulation (immediate-release IR / extended-release XR / long-acting LA / osmotic-release oral system OROS), and manufacturer if you have a preference. Pharmacies stock specific National Drug Codes (NDCs), not generic categories.

When the fill fails.

1. Ask the pharmacist for a partial fill under 21 USC §829(f), as amended by the SUPPORT Act (2018)⁸. They can dispense what they have and complete the remainder within 30 days of the original script date. This is the single most underused tool. Many pharmacists will not offer it unless you ask by name.
2. Ask when their next wholesaler delivery is and whether your exact NDC is on the manifest.
3. Call other pharmacies yourselfwith the exact drug, salt, mg, and formulation. Pharmacists are not permitted to call around for you. Independent and small-chain pharmacies (Hy-Vee, H-E-B, Wegmans) often have stock when the large chains don’t. Mail-order (CVS Caremark, Express Scripts) sometimes does too.
4. If another pharmacy has stock, the prescriber sends a new e-prescription there — or, if the script is unfilled, the August 2023 DEA rule permits a one-time electronic Schedule II transfer between pharmacies. Both must use compatible EPCS systems; many don’t. Some pharmacists will tell you this isn’t possible. The federal rule allows it; the system capability is uneven.
5. If no within-class substitute is available, the prescriber writes a new script for a cross-class option (amphetamine ↔ methylphenidate) or a non-stimulant bridge. This is a re-titration, not a swap.
6. If the gap will affect work, document the interruption with the prescriber in writing — relevant for Americans with Disabilities Act (ADA) accommodation continuity (separate article on workplace accommodations).
7. Do not buy stimulants from unverified online sources. DEA and FDA issued joint warnings in 2023–2024¹² about counterfeit Adderall containing methamphetamine or fentanyl.

Riding out a forced gap

Most people on long-term stimulants will hit at least one gap during the current shortage era. Be honest about what that does. Discontinuation after more than three months of continuous use commonly produces 5 to 14 days of fatigue, low mood, hyperphagia, and executive dysfunction worse than pre-treatment baseline. The DSM doesn’t code a stimulant withdrawal syndrome at therapeutic doses, but the rebound is well documented clinically and in the discontinuation arms of methylphenidate and atomoxetine trials. Adams et al. (2024, JAMA Network Open)⁶ found measurable increases in healthcare use, missed work, and accident-related encounters tied to shortage interruption, worst for patients who had been continuously medicated for over a year.

Strategies during a gap, in rough order of evidence strength: protect sleep (the single best-evidenced intervention); use caffeine for limited bridging at modest doses; lean on behavioural scaffolding — pre-committed schedule, reduced novel-task load, more body-doubling on hard initiations. Non-stimulant bridges (atomoxetine, guanfacine, viloxazine) only help if started before the gap, because of slow onset. What does not have evidence: L-tyrosine supplementation, “dopamine detox” frameworks, kratom microdosing (DEA Schedule discussions ongoing; case reports of toxicity).

The non-stimulant bridges

Short version — the deep dive is the next medication article. Atomoxetine (Strattera, generic since 2017) works on noradrenaline; adult dose 40–100 mg/day; effect builds over 2–6 weeks; moderate efficacy by Cortese SMD around 0.45⁴. Guanfacine ER (Intuniv) is a blood-pressure drug used off-label for adult ADHD at 1–4 mg/day; sedation and lightheadedness are the limiters. Viloxazine ER (Qelbree) was approved for adults in 2022; dose 200–600 mg/day; onset around 2 weeks (Nasser et al., 2022⁹); requires blood pressure and heart rate monitoring and interacts with caffeine.

None of these replace a well-titrated stimulant for most adults. They are bridges, augmentations, or alternatives when stimulants are contraindicated or unavailable. The clinical guidance — AAFP and NICE — recommends trying the other stimulant class before defaulting to a non-stimulant.

The pharmacist / prescriber / insurance scripts

Phrases that get you further than the variants you might naturally use.

To the pharmacist:

• “Can you do a partial fill under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) Act for what you have today?”
• “When’s your next wholesaler delivery, and is [exact drug, mg, NDC if I have it] on the manifest?”
• “If I find another pharmacy with stock, can we do an electronic Schedule II transfer under the 2023 DEA rule?”

To the prescriber:

• “Can you send a 30-day script with the earliest legal fill date so I’m not chasing the calendar?”
• “If [drug] isn’t available, what’s your preferred cross-class option — and would you write a non-stimulant as a hedge?”
• “Can you document the shortage-related interruption in my chart for workplace continuity purposes?”

To the insurance:“My current medication is on the FDA Drug Shortage list. I need a non-formulary substitution authorised — please flag this as shortage-related, not a preference change.” Some plans waive prior-auth for documented shortages; the framing matters.

What we don’t know yet

DEA’s position is that manufacturers underused allocated quota in several recent quarters; manufacturers point to API sourcing, packaging constraints, and labour. Both are partly true; the public record is clearer in investigative reporting than in either party’s statements. Whether the prescription growth documented by the CDC reflects increased recognition or over-diagnosis is a real question elsewhere — for the patient with a script, the answer doesn’t change what to do next. Uptake of the August 2023 transfer rule is uneven; the federal rule allows it but pharmacy systems differ. Counterfeit risk is real per the FDA/DEA warnings but the prevalence in real patient supply is poorly quantified. The shortage’s end date is not on the public record. As of writing, the only honest position is that the system is operating exactly as it’s been operating since October 2022, the playbook above is the working set of moves, and nobody at any level of this can promise the next call will go better.